Searchable abstracts of presentations at key conferences in endocrinology

ea0094p166 | Adrenal and Cardiovascular | SFEBES2023

Malignant pheochromocytoma and paraganglioma – clinical course and outcomes from a tertiary care centre in India

Rajan Remya , Asha Hesarghatta , Pai Rekha , Kapoor Nitin , Cherian Kripa , Paul Thomas , Jebasingh Felix , Thomas Nihal , Sigamani Elanthenral , Sathanam Prisca , MJ Paul , Cherian Anish , Thomas Shawn , Sen Supriya , Chandramohan Anuradha , Singh Ashish , Hepzhibah Julie , Kumar Santhosh , Gowri Mahasampath

Objectives: To study the clinical, biochemical, imaging profile and treatment outcomes of patients with malignant pheochromocytoma and paraganglioma(PPGL). Also, to compare their characteristics with non-malignant PPGL to identify the factors that may predict metastasis.Methods: This retropsective cohort study included 212 patients with PPGL managed at our centre over a period of 10 years(2013-2022). Their clinical, bioc...

ea0098t7 | Trials In Progress | NANETS2023

Phase 1 trial of Pb-212-VMT-alpha-NET in select metastatic or inoperable somatostatin receptor positive tumors

Lin Frank I. , Del Rivero Jaydira , Thomas Anish , Srinivasan Ramaprasad , Charalampos Floudas , Carrasquillo Jorge , Shamis Inna , Zou Joy , Turkbey Baris , Mena Esther , Lindenberg Liza , Chen Clara , Herscovitch Peter , Millo Corina , Pacak Karel

Background: Somatostatin receptors (SSTR) is overexpressed in a number of different tumors, including GI Neuroendocrine Tumors (GI-NET), Pheochromocytoma/Paraganglioma (PPGL), small cell lung cancer (SCLC), renal cell carcinoma (RCC), and certain head and neck cancers (H&N) such as olfactory neuroblastoma. It has been demonstrated that these SSTR-expressing tumors can be treated with beta-emitting radioligand therapy (RLT) that binds to SSTR such as Lu-177-DOTATATE. Howeve...